A carregar...

BRAF Mutations as Predictive Biomarker for Response to Anti‐EGFR Monoclonal Antibodies

Recently, the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommended that patients with epidermal growth factor receptor (EGFR)‐expressing metastatic colorectal cancer could be treated with anti‐EGFR monoclonal antibodies (mAbs) cetuximab and pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: van Brummelen, Emilie M. J., de Boer, Anthonius, Beijnen, Jos H., Schellens, Jan H. M.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507642/
https://ncbi.nlm.nih.gov/pubmed/28576857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!